Core Insights - Elicio Therapeutics announced new immunogenicity data from the Phase 2 AMPLIFY-7P trial for ELI-002 7P, showing strong T cell responses in patients with mKRAS pancreatic ductal adenocarcinoma [1][3][5] - The company also presented preclinical data for ELI-004, indicating its potential to eradicate advanced solid tumors in over 90% of cases [1][8] ELI-002 7P Trial Results - In the AMPLIFY-7P trial, 99% of 90 evaluable patients achieved robust mKRAS-specific T cell responses, with a mean increase of 145-fold over baseline [4][5] - 85% of patients exhibited combined CD4 and CD8 T cell activation, which correlates with clinical activity [5] - 67% of patients responded to all seven mKRAS epitopes, with over 80% response rates to each individual KRAS mutation [4][5] ELI-004 Preclinical Data - ELI-004 demonstrated complete tumor eradication in over 90% of cases in preclinical studies, suggesting long-term protection against recurrence [3][8] - The efficacy of ELI-004 was linked to the presence of CD8 T cells and effective lymphocyte trafficking from lymph nodes [8] HLA Diversity and T Cell Responses - High-resolution HLA typing revealed a diverse HLA repertoire among patients, with 1,132 unique HLAs identified [6] - No significant associations were found between specific HLA types and the magnitude of mKRAS-specific T cell responses, indicating broad applicability of ELI-002 7P [6] Company Overview - Elicio Therapeutics focuses on developing novel immunotherapies targeting high-prevalence cancers, particularly those driven by KRAS mutations [15] - The company's AMP technology aims to enhance immune responses by delivering immunotherapeutics directly to lymph nodes [12][14]
Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC